clarithromycin grindeks õhukese polümeerikattega tablett
grindeks as - klaritromütsiin - õhukese polümeerikattega tablett - 500mg 14tk; 500mg 8tk; 500mg 16tk; 500mg 7tk
clarithromycin grindeks õhukese polümeerikattega tablett
grindeks as - klaritromütsiin - õhukese polümeerikattega tablett - 250mg 16tk; 250mg 8tk; 250mg 14tk
memantine grindeks õhukese polümeerikattega tablett
grindeks as - memantiin - õhukese polümeerikattega tablett - 10mg 40tk; 10mg 56tk; 10mg 98tk; 10mg 100tk; 10mg 90tk; 10mg 28tk; 10mg 14tk; 10mg 60tk; 10mg 20tk; 10mg 112tk; 10mg 50tk
valsartan hydrochlorothiazide liconsa 160mg/25mg õhukese polümeerikattega tablett
laboratorios liconsa s.a. - valsartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 160mg+25mg 28tk; 160mg+25mg 98tk; 160mg+25mg 14tk; 160mg+25mg 280tk; 160mg+25mg 30tk; 160mg+25mg 56tk
valsartan hydrochlorothiazide liconsa 80mg/12.5mg õhukese polümeerikattega tablett
laboratorios liconsa s.a. - valsartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 80mg+12,5mg 280tk; 80mg+12,5mg 98tk; 80mg+12,5mg 28tk; 80mg+12,5mg 14tk; 80mg+12,5mg 56tk
memantine apotex 20 mg õhukese polümeerikattega tablett
apotex europe b.v. - memantiin - õhukese polümeerikattega tablett - 20mg 14tk; 20mg 28tk; 20mg 56tk; 20mg 84tk; 20mg 98tk
memantine apotex 10 mg õhukese polümeerikattega tablett
apotex europe b.v. - memantiin - õhukese polümeerikattega tablett - 10mg 112tk; 10mg 28tk; 10mg 98tk
tektrotyd radiofarmatseutiline komplekt
narodowe centrum badan jadrowych - tehneetsium(99mtc)hynic-oktreotiid - radiofarmatseutiline komplekt - 20mcg 1tk
iodopol kõvakapsel
narodowe centrum badan jadrowych - naatriumjodiid (131i) - kõvakapsel - 1tk
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosupressandid - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).